Literature DB >> 27467933

Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation.

M C A Wouters1, F L Komdeur2, M de Bruyn2, H W Nijman2.   

Abstract

Outcome of cytoreductive surgery, treatment sequence and the differentiation status of T cells are key factors to take into account when studying the prognostic value of tumor-infiltrating lymphocytes (TIL) in high grade serous ovarian cancer.

Entities:  

Keywords:  CD27; high-grade serous epithelial ovarian cancer; neo-adjuvant chemotherapy; surgical cytoreduction; tumor-infiltrating lymphocytes

Year:  2016        PMID： 27467933      PMCID： PMC4910701          DOI： 10.1080/2162402X.2015.1122863

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.

Authors:  Li-Zhen He; Naseem Prostak; Lawrence J Thomas; Laura Vitale; Jeffrey Weidlick; Andrea Crocker; Catherine D Pilsmaker; Sarah M Round; Alison Tutt; Martin J Glennie; Henry Marsh; Tibor Keler
Journal:  J Immunol       Date:  2013-09-11       Impact factor: 5.422

2.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

3.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

4.  Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.

Authors:  Maartje C A Wouters; Fenne L Komdeur; Hagma H Workel; Harry G Klip; Annechien Plat; Neeltje M Kooi; G Bea A Wisman; Marian J E Mourits; Henriette J G Arts; Maaike H M Oonk; Refika Yigit; Steven de Jong; Cornelis J M Melief; Harry Hollema; Evelien W Duiker; Toos Daemen; Marco de Bruyn; Hans W Nijman
Journal:  Clin Cancer Res       Date:  2015-09-18       Impact factor: 12.531

5.  CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Authors:  Qunrui Ye; De-Gang Song; Mathilde Poussin; Tori Yamamoto; Andrew Best; Chunsheng Li; George Coukos; Daniel J Powell
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

6.  Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

Authors:  Ninke Leffers; Marloes J M Gooden; Renske A de Jong; Baukje-Nynke Hoogeboom; Klaske A ten Hoor; Harry Hollema; H Marieke Boezen; Ate G J van der Zee; Toos Daemen; Hans W Nijman
Journal:  Cancer Immunol Immunother       Date:  2008-09-13       Impact factor: 6.968

Review 7.  Lineage relationship of effector and memory T cells.

Authors:  Nicholas P Restifo; Luca Gattinoni
Journal:  Curr Opin Immunol       Date:  2013-10-20       Impact factor: 7.486

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.

Authors:  Laura A Vitale; Li-Zhen He; Lawrence J Thomas; Jennifer Widger; Jeffrey Weidlick; Andrea Crocker; Thomas O'Neill; James Storey; Martin J Glennie; Deanna M Grote; Stephen M Ansell; Henry Marsh; Tibor Keler
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

10.  Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.

Authors:  Markus Riester; Wei Wei; Levi Waldron; Aedin C Culhane; Lorenzo Trippa; Esther Oliva; Sung-Hoon Kim; Franziska Michor; Curtis Huttenhower; Giovanni Parmigiani; Michael J Birrer
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506
  10 in total
  2 in total

1.  Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.

Authors:  Fiona R James; Mercedes Jiminez-Linan; Jennifer Alsop; Marie Mack; Honglin Song; James D Brenton; Paul D P Pharoah; H Raza Ali
Journal:  BMC Cancer       Date:  2017-09-20       Impact factor: 4.430

2.  Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome.

Authors:  Kim L Brunekreeft; Sterre T Paijens; Maartje C A Wouters; Fenne L Komdeur; Florine A Eggink; Joyce M Lubbers; Hagma H Workel; Elisabeth C Van Der Slikke; Noor E J Pröpper; Ninke Leffers; Julien Adam; Harry Pijper; Annechien Plat; Arjan Kol; Hans W Nijman; Marco De Bruyn
Journal:  Oncoimmunology       Date:  2020-05-13       Impact factor: 8.110
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.